|
|
|
05.05.26 - 20:24
|
Demant Reports Strong Q1 Revenue Growth (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Demant A/S (WILYY) on Tuesday reported an interim update with revenue increasing from last year, supported by strong performance in its Hearing Aids business.The company rep......
|
|
|
17.04.26 - 17:12
|
XETR: Deletion of Instruments from XETRA - 17.04.2026 -1- (XETRA)
|
|
|
The following instruments on XETRA do have their last trading day on 17.04.2026.
Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 17.04.2026.
ISIN Name
US0028962076 Abercrombie & Fitch Co.
US0162551016 Align Technology Inc.
US02043Q1076 Alnylam Pharmaceuticals Inc.
US0255371017 American Electric Power Co. Inc.
US0311001004 AMETEK Inc.
US0530151036 Automatic Data Processing Inc.
GB00BPQY8M80 Aviva PLC
IE00BD1RP616 Bank of Ireland Group PLC
US14448C1045 Carrier Global Corp.
US8085131055 Charles Schwab Corp.
US16119P1084 Charter Communications Inc. [Del.]
US1713401024 Church & Dwight Co. Inc.
US1255231003 Cigna Group, The
US1729081059 Cintas Corp.
US12572Q1058 CME Group Inc.
US1924461023 Cognizant Technology Solutions Corp.
US2091151041 Consolidated Edison Inc.
US22052L1044 Corteva Inc.
US1264081035 CSX Corp.
US2310211063 Cummins Inc.
US2435371073 Deckers Outdoor Corp.
DK0060738599 Demant AS
US2533931026 Dics Sporting Goods Inc.
US2566771059 Dollar General Co...
|
|
|
01.04.26 - 17:54
|
The Nomination Committee proposes two new Board members (Cision)
|
|
|
Vitrolife AB (publ) ("Vitrolife") today announced that its Nomination Committee proposes the election of Nicklas Hansen and David T. Hansen as new Board members. The Committee further proposes the re-election of Jón Sigurdsson as Chairman of the Board, as well as all current Board members except Lars Holmqvist, who has decided not to stand for re-election at the 2026 Annual General Meeting.
Nicklas Hansen is Chief Investment Officer at Vitrolife's largest shareholder, William Demant Invest A/S, where he is responsible for its investment portfolio. He has held several positions at William...
|
|
|
05.03.26 - 22:03
|
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (Business Wire)
|
|
|
Positive RG6501 (OpRegen® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025
Achieved First Milestone Under Worldwide Collaboration with Genentech Based on RG6501 (OpRegen Cell Therapy) Program Manufacturing and Clinical Advancements
Successfully Demonstrated the High-Scale Production Potential of Our Proprietary AlloSCOPE™ Manufacturing Platform
Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for Sensorineural Hearing Loss
Initiated Manufacturing Scale Research Project in Type 1 Diabetes
Treated First-Ever Chronic SCI Patient in OPC1 DOSED Device Safety Study
Current Cash and Equivalents Expected to Support Operations Into Second Quarter 2028
CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today repo...
|
|
|
|
|
03.02.26 - 08:06
|
Demant A/S Full Year Income Falls (AFX)
|
|
|
BRUSSELS (dpa-AFX) - Demant A/S (DEMANT.CO) released a profit for full year that Drops, from last yearThe company's bottom line came in at DKK2.367 billion, or DKK11.20 per share. This compares wi......
|
|
|
22.12.25 - 13:06
|
ACCO Brands to Acquire EPOS (Business Wire)
|
|
|
EPOS offers premium commercial and enterprise audio solutions
Transaction enhances and broadens our Kensington computer accessories portfolio into the large global enterprise headset category
Provides key third-party certifications across major unified communications platforms
Attractive purchase price with ultimate synergy savings of approximately $15 million
LAKE ZURICH, Ill.--(BUSINESS WIRE)--#ACCO--ACCO Brands Corporation (NYSE: ACCO) a global leader in branded office and learning products and technology accessories, today announced it has entered into a definitive agreement to acquire EPOS from Demant A/S, a leading Danish hearing healthcare company.
Based in Copenhagen, Denmark, EPOS provides a comprehensive range of premium enterprise wired and wireless headsets, and other audio solutions, that build on over a century of research in psychoacoustics. The EPOS product line is designed to reduce listening fatigue, improve voice clarity and support cognitive performance. The combination of technologica...
|
|
|
|
|
06.11.25 - 22:06
|
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
|
|
|
Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025
Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for Sensorineural Hearing Loss
Initiated Manufacturing Scale Project in Type 1 Diabetes Cell Therapy
CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today reported its third quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
“It has been a productive third quarter for the Lineage team,” stated Brian M. Culley, Lineage CEO. “Last quarter, I outlined five areas of focus through the end of this year, and I am pleased to report that we delivered on several of these during the thi...
|
|
|
|
|
22.10.25 - 12:36
|
Impilo acquires Oticon Medical from Demant (Cision)
|
|
|
Stockholm, 2025-10-22 - Impilo is pleased to announce that it has agreed to acquire Oticon Medical, a global leader in bone-anchored hearing solutions (BAHS), from Demant A/S. This transformative transaction represents the first investment from Impilo's recently raised Fund II and marks the beginning of an exciting new chapter for Oticon Medical. Building on the company's legacy of innovation and patient care, Impilo will support Oticon Medical in its transition to a standalone company while accelerating growth, advancing next-generation technologies, and strengthening its position as a...
|
|
|
|
|
04.09.25 - 23:51
|
XETR: NEW INSTRUMENT AVAILABLE - 05.09.2025 - DK0060738599 (XETRA)
|
|
|
Das Instrument WDH1 DK0060738599 DEMANT AS A DK 0,2 EQUITY hat seinen ersten Handelstag am 05.09.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG SKA0, SettlCurr EUR, CCP Y
The instrument WDH1 DK0060738599 DEMANT AS A DK 0,2 EQUITY has its first trading date on 05.09.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG SKA0, SettlCurr EUR, CCP Y...
|
|
|
26.08.25 - 14:03
|
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss (Business Wire)
|
|
|
Three-year term intended to advance preclinical development of ReSonance
Up to $12 million of development costs to be contributed by William Demant Invest
CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious neurological and ophthalmic conditions, today announced that it has entered into a research collaboration with and through an investment from William Demant Invest A/S (WDI). WDI is an evergreen investor and the holding company for William Demant Foundation's investment activities – a majority shareholder of the world-leading hearing healthcare company, Demant A/S.
The parties will jointly advance Lineage's auditory neuronal cell transplant, ReSonance (ANP1), for the treatment of hearing loss. The multi-year research collaboration covers preclinical development activities, including cell manufacturing, p...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
